Alume Receives Commercialization Readiness Program Grant from the NIH to Support Commercialization of ALM-488 to Highlight Nerves

[La Jolla, CA][September 9, 2022] Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M Commercialization Readiness Program (CRP) Grant from the Small Business Innovation Research (SBIR) of the National Institute of Neurological Disorders and Stroke (NINDS). This grant will support Alume's commercialization efforts of its novel nerve illumination technology in surgery. The Principal Investigators on this grant are Michael Whitney, PhD, Scientific Co-Founder and Vice President of Discovery and Brett Berman, MD, Co-Founder and Chief Medical Officer at Alume.